GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines The companies aim to develop a portfolio of up to ten candidates (July 31, 2024) | By Jen Brogan. Bringing together GSK’s expertise in disease and development capability via Flagship’s ecosystem of bioplatform companies, the collaboration aims to develop
Pharmaceuticals from marine sources: past, present and future An overview of why marine natural products are an attractive prospect for future drug discovery, including history of the field, successes in the clinic and challenges associated with gaining clinical approval.
Boehringer inks $1.3B acquisition of Nerio and its preclinical checkpoint inhibitors (July 29, 2024) | By James Waldron. Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece” of its immune-oncology portfolio. Nerio has been working on small molecules that
